Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism

IntroductionSuraxavir Marboxil (GP681) is a prodrug metabolized to GP1707D07, which inhibits influenza viral replication by targeting cap-dependent endonuclease through a single oral dose. This study assesses the in vivo drug-drug interaction (DDI) potential between GP681 (including its major metabo...

詳細記述

書誌詳細

出版年:	Frontiers in Pharmacology
主要な著者:	Mai Han, Gang Cui, Yan Zhao, Xianbo Zuo, Xiaoxue Wang, Xin Zhang, Na Mi, Jiangli Jin, Chunyan Xiao, Jing Wang, Wei Wu, Yajuan Li, Jintong Li
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2025-04-01
主題:	DDI (drug-drug interaction) itraconazole Suraxavir Marboxil (GP681) safety genetic polymorfism pharmacokinetic
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1505557/full